Table 1.
Demographic, clinical, and MRI characteristics of study subjects with thalamic lesions.
| All | RRMS | SPMS | |
|---|---|---|---|
| N | 90 | 61 | 29 |
| Gender (M/F) | 23/67 | 13/48 | 10/19 |
| Age, years | 42.3 (9.2) | 40 (8.6) | 47.1 (8.7) |
| Disease duration, years | 9.1 (9.2) | 5.2 (5.7) | 17.6 (9.6) |
| EDSS score, median (range) | 2.5 (8) | 2.1 (1.1) | 4.5 (6) |
| SDMT, Z-score | −0.04 (1.5) | 0.5 (1.1) | −1.3 (1.4) |
| Education | 15.9 (2.7) | 16.2 (2.8) | 15.2 (2.5) |
| Caucasian: African American: Asian | 87:2:1 | 59:2:0 | 28:0:1 |
| Therapy | |||
| Dimethyl Fumarate | 18 | 14 | 4 |
| Natalizumab | 16 | 12 | 4 |
| Glatiramer Acetate | 18 | 12 | 6 |
| Interferon Beta-1a | 16 | 10 | 6 |
| Cyclophosphamide | 1 | 0 | 1 |
| Monoclonal Antibody | 2 | 0 | 2 |
| Immunosuppressant | 1 | 1 | 0 |
| No Treatment | 18 | 12 | 6 |
Abbreviations: RRMS = relapsing remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; EDSS = Expanded Disability Status Scale; All values are reported as mean (SD) if not as otherwise noted